Rare Daily Staff
United Therapeutics is strengthening its arsenal by agreeing to acquire orphan drug company SteadyMed for $141 million and up to an additional $75 million in a milestone.
Under the terms of the agreement, United Therapeutics will pay $4.46 per share in cash at closing and up to an additional $2.63 per share in cash upon the achievement of a milestones related to the commercialization of SteadyMed’s pulmonary arterial hypertension combination therapy Trevyent in a deal worth up to $216 million.
Trevyent is a development-stage drug-device combination product that combines SteadyMed’s two-day, single use, disposable PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue, for the subcutaneous treatment of pulmonary arterial hypertension. The milestone payment tied to Trevyent is worth a total of $75 million.
PAH is rare progressive that affect the ability of the heart to pump blood to the lungs because of a narrowing of the blood vessels and an elevation of blood pressure. United Therapeutics already market four products for PAH
“We are optimistic about acquiring SteadyMed and adding Trevyent to our pipeline of products to treat PAH,” said Martine Rothblatt, chairman and CEO of United Therapeutics. “We are especially impressed with SteadyMed’s management team and global supply chain. Trevyent fits in well with our mission, and we look forward to bringing the product to the maximum number of patients as soon as possible.”
The board of SteadyMed has unanimously approved the merger agreement and unanimously recommended that shareholders adopt the merger agreement. SteadyMed shareholders owning approximately 43.3 percent of the ordinary shares of SteadyMed have entered into an agreement to vote their shares in favor of the transaction.
The transaction is subject to customary closing conditions, including approval by SteadyMed’s shareholders and the expiration or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and is expected to be completed in the third quarter of this year.
“United Therapeutics has always been at the forefront of developing therapies to treat PAH, and we are delighted at the prospect of our companies coming together, as one, to continue that mission,” said Jonathan M.N. Rigby, president and CEO of SteadyMed. “We believe that this proposed acquisition will help us realize our commitment to bring Trevyent to market to improve the lives of patients with PAH.”
May 2, 2018
Photo: Martine Rothblatt, CEO of United Therapeutics (By Andrea Chung -20140912-Martine-Rothblatt-5773.jpg: Owner and Copyright holder is Andre Chung derivative work: Bit7ocker – This file was derived from -20140912-Martine-Rothblatt-5773.jpg)
Related
Top 10 Takeaways from the 2023 RARE Health Equity Forum
Whether you attended in person or watched the live stream, we hope that you now have ideas […]
Read moreTop 10 Takeaways from the 2023 RARE Advocacy Summit
Did you LEVEL UP while attending or live streaming the 2023 RARE Advocacy Summit? We certainly did! […]
Read moreCyclo Therapeutics and Applied Molecular Transport Agree to Merge
Rare Daily Staff Cyclo Therapeutics, a clinical stage company focused on developing therapies for rare and neurological […]
Read moreGlobal Genes Team Collaborates with Homocystinuria Community and Researchers on Report
The Homocystinuria (HCU) community, Dr. Kim Chapman (Children’s National Rare Disease Institute), Dr. Mary Chapman (UPMC Children’s […]
Read moreBreakthroughs Begin with You: Cure SMA Celebrates Spinal Muscular Atrophy Awareness Month
August is Spinal Muscular Atrophy (SMA) Awareness Month, so Global Genes invited Cure SMA, a Global Advocacy […]
Read moreFive Resources For Grieving
August 30 is National Grief Awareness Day. As there are many types of grief and no two […]
Read moreAutoinflammatory Alliance: Bringing Hope and Changing Lives For Those Living With Autoinflammatory Disease
August is Autoinflammatory Disease Awareness Month. One of the more common rare diseases that falls into the […]
Read moreAutoinflammatory Disease: The Invisible Epidemic
August is Autoinflammatory Disease Awareness Month. One of the more common rare diseases that falls into the […]
Read moreImplementing a Decentralized Clinical Trial Design for Children with SCN2A & SCN8A Developmental and Epileptic Encephalopathies (DEEs)
contribution from Praxis Precision Medicines Praxis Precision Medicines is a clinical biopharmaceutical company with the largest portfolio […]
Read more